- Home
- NKTR
NKTR
Nektar Therapeutics
as 07-26-2024 4:00pm EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 200.6M | IPO Year: | 1994 |
| Target Price: | $3.50 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.41 - $1.93 | Next Earning Date: | 08-06-2024 |
| Revenue: | $90,167,000 | Revenue Growth: | 1.51% |
| Revenue Growth (this year): | -16.08% | Revenue Growth (next year): | -10.43% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | NKTR | President & CEO | May 17 '24 | Sell | $1.75 | 16,650 | $29,137.50 | 863,239 | SEC Form 4 |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | May 17 '24 | Sell | $1.75 | 7,355 | $12,871.25 | 257,670 | SEC Form 4 |
| Deep Track Capital, LP | NKTR | 10% Owner | May 10 '24 | Sell | $1.78 | 56,000 | $99,629.60 | 18,344,000 | SEC Form 4 |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Feb 20 '24 | Sell | $0.68 | 9,014 | $6,129.52 | 265,025 | SEC Form 4 |
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Feb 20 '24 | Sell | $0.68 | 7,606 | $5,172.08 | 236,674 | SEC Form 4 |
| ROBIN HOWARD W | NKTR | President & CEO | Feb 20 '24 | Sell | $0.68 | 20,033 | $13,622.44 | 879,889 | SEC Form 4 |
| ROBIN HOWARD W | NKTR | President & CEO | Nov 17 '23 | Sell | $0.49 | 19,877 | $9,739.73 | 899,922 | SEC Form 4 |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Nov 17 '23 | Sell | $0.49 | 9,646 | $4,726.54 | 274,039 | SEC Form 4 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
Nektar Therapeutics' (NASDAQ:NKTR) large institutional owners must be happy as stock continues to impress, up 13% over the past week
PR Newswire
a month ago
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
2 months ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Simply Wall St.
2 months ago
Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Simply Wall St.
2 months ago
Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.